Quantoom
Quantoom Biosciences is reinventing mRNA production by developing the NfinityTM Platform that encompasses DNA and RNA manufacturing and formulation, along with critical reagent supply, from sequence to large-scale production. In December 2021, we expanded our team with the acquisition of SynHelix which specializes in synthetic DNA and enzyme engineering. We are a team of scientists, engineers and clinicians committed to solving some of the biggest DNA and RNA production challenges facing vaccines and therapeutics, by delivering greater access and autonomy to mRNA technology. Our facilities are strategically located in Belgium and France, in the heart of Europe, benefiting from an exceptional biotech ecosystem. The company is part of Univercells Group, with the mission of ensuring that everyone has access to biologics everywhere in the world.
